Trading Halt

Key points

• Recce Pharmaceuticals requests trading halt pending announcement of Phase II ABSSSI clinical trial data
• Trading halt to remain in place until earlier of market open on 17 February 2025 or announcement release
• Company not aware of any reason why trading halt should not be granted

Full summary

Recce Pharmaceuticals Ltd has requested a trading halt on its securities (ASX: RCE) pending the release of a material announcement relating to Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial data. The trading halt will remain in place until the earlier of the commencement of normal trading on Monday, 17 February 2025 or the release of an announcement by the company regarding the trial results. Recce Pharmaceuticals has stated that it is not aware of any reason why the trading halt should not be granted, and that the announcement has been approved for release by the company's board. No further details have been provided regarding the nature or potential impact of the upcoming announcement.